T cell receptor alpha variable 16 (TRAV16)

T cell receptor alpha variable 16 (TRAV16) is a gene segment encoding a variable domain of the alpha chain of the T cell receptor (TCR), an essential component of the adaptive immune system. The TCR is a heterodimeric complex (typically composed of alpha and beta chains) expressed on the surface of T lymphocytes, responsible for recognizing peptide antigens presented by major histocompatibility complex (MHC) molecules on antigen presenting cells. TRAV16 contributes to the vast diversity of antigen recognition by offering variability to the antigen-binding site. This segment undergoes somatic DNA recombination with joining (J) segments during T cell development, generating unique TCR molecules per cell[1][2]. Binding of the TCR, utilizing its variable domains, to a peptide/MHC complex initiates intracellular signaling cascades critical for T cell activation, differentiation, and effector functions, including immune surveillance against infections, cancer, and other diseases[1][2]. The TRAV16 segment is one of multiple variable genes that, through combinatorial and junctional diversity, enable recognition of a broad array of antigens, playing a core role in adaptive immunity[1][2][4][5]. Notes: - No direct evidence indicates that drugs selectively interact with TRAV16 itself; TCR-directed immunotherapies (e.g., bispecific antibodies, engineered T cells) generally interact with entire TCR complexes rather than with individual variable gene segments. - TRAV16, as a variable gene segment, serves primarily as a marker in immune repertoire studies or T cell clonality assays, rather than as a direct therapeutic target or routinely used biomarker for clinical efficacy. - Safety concerns relate generally to therapies modulating TCR function, not to targeting TRAV16 individually[1][2].

Other names

T cell receptor alpha variable 16TRAV16TCRAV16S1TCRAV9S1

Immune modulation through T cell activation or inhibition (for drugs targeting associated TCR complexes)